Insulin management devices maker Insulet (NSDQ:PODD) is highly optimistic about the future, foreseeing "record sales" in upcoming quarters as the company boosts its manufacturing, extends distribution agreements and fortifies its market against the competition.
Insulin Management
The hack-able body: Are device makers doing enough to shield patients from hackers?
Karen Sandler was 31 years old, working at a non-profit organization providing free legal help to computer programmers, when she was diagnosed with an enlarged heart and informed that she’d need a machine to help keep her alive.
Her mother accompanied her the day a doctor recommended that Sandler undergo surgery to implant a medical device into her chest. He handed Sandler a pager-sized machine called a cardioverter defibrillator – a miniature, implantable equivalent of having EMTs follow her around all day with defibrillator paddles should her heart stop.
(page 2) The hack-able body
Diabetes: PositiveID makes stride toward artificial pancreas | MassDevice.com On Call
MASSDEVICE ON CALL — PositiveID (OTC:PSID) put the finishing touches on a first-in-class fully synthetic glucose sensing system, a critical component of its ongoing efforts toward developing an artificial pancreas for people with diabetes.
The company’s prototype, developed in partnership with Receptors LLC, can now sense and respond to glucose in human plasma, where it had previously only been demonstrated in a model blood plasma matrix.
MassDevice.com +3 | The top 3 med-tech stories for March 1, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Diabetes: Medtronic creeps closer to an artificial pancreas for the U.S. market
Medtronic Inc. (NYSE:MDT) crept closer to realizing an artificial pancreas for diabetics with the release of clinical trial results finding that its MiniMed Paradigm insulin delivery system met clinical endpoints with low-glucose suspend technology.
Diabetes: Insulet inks deal with J&J’s LifesScan for next-gen OmniPod
Orthopedists spend billions on unneeded tests in self-defense | MassDevice.com On Call
MASSDEVICE ON CALL — Orthopedic surgeons may be spending billions each year ordering unnecessary tests in order to protect themselves from potential liability lawsuits, a national survey found
More than ¾ of survey respondents said they would order fewer tests "if there was significant medical liability reform."
Researchers calculated that the "defensive medicine" efforts cost Medicare about $2.1 billion each year, MedPageToday reported.
Insulet gains after paring Q4, 2011 losses | Earnings Roundup
Wall Street investors drove Insulet (NSDQ:PODD) shares up nearly 4% today ahead of the insulin management company’s 4th-quarter and full-year earnings statement.
Bedford, Mass.-based Insulet posted losses of $14.3 million, or 30 cents per share, on sales of $47.2 million for the 3 months ended Dec. 31, 2011, adding 70% to the top line and shaving 31.3 percent off of its losses, compared with the same period in 2010.
Insulet gains after paring Q4, 2011 losses
Wall Street investors drove Insulet (NSDQ:PODD) shares up nearly 4% today ahead of the insulin management company’s 4th-quarter and full-year earnings statement.
Bedford, Mass.-based Insulet posted losses of $14.3 million, or 30 cents per share, on sales of $47.2 million for the 3 months ended Dec. 31, 2011, adding 70% to the top line and shaving 31.3 percent off of its losses, compared with the same period in 2010.
MassDevice.com +7 | The top 7 med-tech stories for the week of January 16, 2012
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.